

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KELUN-BIOTECH**  
**科伦博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

## **AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) dated August 3, 2023 (the “**Announcement**”) in relation to the full exercise of the Over-allotment Option in respect of an aggregate of 3,366,900 H Shares of the Company. Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Announcement.

Upon full exercise of the Over-allotment Option, the registered capital and total number of issued shares of the Company were changed to RMB219,195,499 and 219,195,499 Shares, respectively. To reflect such changes in the registered capital and capital structure of the Company, corresponding amendments (the “**Amendments**”) were made to the articles of association of the Company (the “**Articles of Association**”). The Company has completed the registration and filing procedures with the Administration for Market Regulation of Chengdu in respect of the Amendments.

In accordance with the shareholders’ resolutions of the Company dated February 15, 2023 and June 12, 2023 as disclosed in the prospectus of the Company dated June 29, 2023, the general meeting of the Company has authorized the board of directors of the Company (the “**Board**”) and persons authorized by the Board to make corresponding adjustments and amendments to the Articles of Association based on the actual results of the Global Offering, including but not limited to the wordings, sections, articles, conditions precedent, registered capital and capital structure of the Articles of Association, pursuant to which the Company announces the Amendments as set out below. In accordance with the aforementioned authorization granted at the general meeting of the Company, the Amendments do not require additional approval at the general meeting of the Company.

Article No.	Before Amendments	After Amendments
<b>Article 6</b>	The registered capital of the Company is RMB215,828,599 (if the over-allotment option is exercised in full, then the registered capital of the Company shall be RMB219,195,499).	The registered capital of the Company is <del>RMB215,828,599 (if the over-allotment option is exercised in full, then the registered capital of the Company shall be RMB219,195,499)</del> RMB219,195,499.
<b>Article 20</b>	Upon completion of the initial public offering of H shares, assuming the over-allotment option is not exercised, the capital structure of the Company on the listing date will be: 215,828,599 ordinary shares, comprising 155,138,328 unlisted shares and 60,690,271 H shares; the registered capital of the Company on the listing date will be RMB215,828,599; after the exercise of the over-allotment option, the capital structure of the Company will be: 219,195,499 ordinary shares, comprising 155,138,328 unlisted shares and 64,057,171 H shares.	Upon completion of the initial public offering of H shares, <del>assuming the over-allotment option is not exercised, the capital structure of the Company is on the listing date will be: 215,828,599 ordinary shares, comprising 155,138,328 unlisted shares and 60,690,271 H shares; the registered capital of the Company on the listing date will be RMB215,828,599;</del> and after the exercise of the over-allotment option, the capital structure of the Company <del>will be</del> <b>is</b> : 219,195,499 ordinary shares, comprising 155,138,328 unlisted shares and 64,057,171 H shares.

The full text of the amended Articles of Association is available on the Company's website at <http://kelun-biotech.com> and the Stock Exchange's website at <http://www.hkexnews.hk>.

Shareholders should be aware that the Articles of Association are written in Chinese. In the event of discrepancies between the Chinese version and the English translation of the Articles of Association, the Chinese version shall prevail.

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive director*

Hong Kong, August 31, 2023

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive director, Dr. GE Junyou and Dr. WANG Jingyi as executive directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive directors.*